Japan PPI inflation slips to 11-mth low in July
Journey Medical (TASE:BLWV) Corp (NASDAQ:DERM) President and CEO Claude Maraoui recently sold shares amounting to $360,761, according to an SEC filing. The transactions occurred over three consecutive days, from March 3 to March 5, 2025. The stock, which has gained nearly 50% over the past year and currently trades at $5.23, has shown strong momentum according to InvestingPro data.
On March 3, Maraoui sold 23,508 shares at a weighted average price of $5.19, with the price range for the day spanning from $5.00 to $5.57. The following day, March 4, saw the sale of 28,901 shares at an average price of $5.04, within a range of $5.00 to $5.17. Finally, on March 5, Maraoui sold 18,147 shares at an average price of $5.13, with prices ranging from $5.02 to $5.26. With analyst targets ranging from $9 to $11, the stock appears to be trading below consensus expectations.
These sales were conducted automatically to satisfy tax withholding obligations related to the vesting of restricted stock units, in accordance with the company’s corporate policies. Following these transactions, Maraoui retains ownership of 2,092,874 shares of Journey Medical Corp, which currently has a market capitalization of $106 million. The company’s next earnings report is scheduled for March 20, 2025. For deeper insights into DERM’s valuation and growth prospects, check out the comprehensive research available on InvestingPro.
In other recent news, Journey Medical Corporation announced the FDA approval of Emrosi™, a new treatment for moderate-to-severe papulopustular rosacea in adults. This approval follows the successful completion of two Phase 3 clinical trials, which demonstrated that Emrosi™ met all primary and secondary endpoints. The trials showed that the treatment was statistically superior to both Oracea® capsules and a placebo. The company plans to launch Emrosi™ in the market by early spring of 2025. The treatment involves a 40 mg Minocycline Hydrochloride Modified-Release Capsule, administered once daily for 16 weeks. The trials reported no significant safety issues, with adverse events similar across all treatment groups. The most common adverse reaction noted was dyspepsia. Journey Medical Corporation, founded by Fortress Biotech (NASDAQ:FBIO), continues to focus on marketing FDA-approved pharmaceutical products for dermatological conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.